Clinical Trials Logo

Stage IV Non-small Cell Lung Cancer clinical trials

View clinical trials related to Stage IV Non-small Cell Lung Cancer.

Filter by:

NCT ID: NCT03305380 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Start date: September 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The investigators will develop a radiomics signature for immune checkpoint-induced pneumonitis in 40 patients with a pulmonary event under anti-PD1 or anti-PD-L1 (cases) and 40 patients without a pulmonary event under anti-PD1 or anti-PD-L1 (controls). On the basis of the case-control study of patients treated with anti-PD1 or anti-PD-L1, they will further optimise the model using reinforcement machine learning. The model will then be validated in 300 prospective patients.

NCT ID: NCT03199651 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

BLCIO
Start date: July 17, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.

NCT ID: NCT03176173 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

Start date: June 28, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.

NCT ID: NCT03154190 Recruiting - Clinical trials for Acute Myeloid Leukemia

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Start date: December 15, 2016
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.

NCT ID: NCT03137771 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without stereotactic body radiation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving maintenance chemotherapy and stereotactic body radiation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.

NCT ID: NCT03121417 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

Start date: July 21, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial is studying blood and tumor tissue from patients with advanced non-small cell lung cancer who are treated with nivolumab to better understand how nivolumab works. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread by turning on the immune system (T cells). We want to study the effects of nivolumab on the immune system (T cells) by collecting blood samples and samples from patients' tumors.

NCT ID: NCT03119519 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Local Definitive Radiotherapy in Synchronous Oligometastatic Non-small-cell Lung Cancer

Start date: September 2017
Phase: Phase 3
Study type: Interventional

Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.

NCT ID: NCT03087708 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Start date: October 13, 2017
Phase: Phase 3
Study type: Interventional

This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.

NCT ID: NCT03050060 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Start date: June 9, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate and nivolumab in treating patients with melanoma, lung cancer, or kidney cancer that has spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving hypofractionated radiation therapy, nelfinavir mesylate, and nivolumab may work better in treating patients with melanoma, lung, or kidney cancer.

NCT ID: NCT03049618 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.